Clinical Trial Update: A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia [Phase 3]

View source ↗

Summary

Phase III study of PA21 in hemodialysis patients with hyperphosphatemia has completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• PA21 (PA21)

Snippet

Sponsor: Kissei Pharmaceutical Co., Ltd. | Conditions: Hemodialysis, Hyperphosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2018-10-09